Cancer
Researchers from Sun Yat-sen University Cancer Center have made a significant breakthrough in the treatment of glioblastoma, a highly aggressive form of brain cancer. By developing a novel biomimetic delivery system, the team has been able to activate glioma-associated macrophages (GAMs) to enhance the repolarization and phagocytic abilities of these
Cancer
Johnson & Johnson is set to showcase 16 presentations at the European Society for Medical Oncology (ESMO) 2025 Congress, highlighting advances across its industry-leading solid tumor pipeline. The company has entered a new era in oncology, delivering bold advances in solid tumors, including head and neck, lung, bladder, and prostate
Cancer
A team of researchers at the Beijing Cancer Hospital has developed a novel mRNA-based therapeutic vaccine, MTS107, which has shown promising results in treating human papillomavirus (HPV)-driven cancers, including head and neck and cervical cancers. The vaccine, which encodes mutated E6/E7 antigens from HPV16/18, has been shown
Cancer
Researchers at the Peking Union Medical College Hospital have developed exosomes-incorporated biomaterials that have shown significant promise in enhancing cancer immunotherapy. These novel platforms combine the benefits of both biomaterials and exosomes, overcoming their limitations. The study, published in Nano Today, highlights the potential of these nanoplatforms to induce immunogenic
Cancer
A gentle and open approach guides Cancer Zodiac sign's day as they navigate emotions and practical decisions. With a focus on calm and patient energy, individuals can build trust with loved ones, make sensible choices, and tackle tasks with ease. Cancers are encouraged to speak honestly and listen
Cancer
Research at Al-Ahliyya Amman University has shed light on the role of kinesin superfamily proteins in cancer, particularly in mediating sensitivity to chemotherapy. The study found that aberrant expression of these proteins contributes to resistance to chemotherapy in various types of cancer, including breast, lung, and prostate cancers. The research
Cancer
A 65-year-old man with diabetic nephropathy and recurrent gastric cancer with liver metastases has undergone a unique treatment regimen involving nivolumab plus modified FOLFOX6 therapy, with encouraging results despite the patient's challenging medical condition. According to a case report published in Internal Medicine, the patient's cancer
Cancer
The American Oncology Institute (AOI) at ASCOMS Jammu has made a significant stride in complex cancer treatment by successfully performing a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedure on a patient with advanced ovarian cancer. This achievement highlights AOI Jammu's growing capabilities in delivering high-end cancer care and offering sophisticated
Cancer
Investigators at the University of California have published a new report on biotechnology and cancer gene therapy, revealing a promising strategy for targeting cancers driven by herpesviruses. The research team has devised a cancer gene therapy vector using the adeno-associated virus (AAV), which capitalizes on the latency-associated nuclear antigen (LANA)
Cancer
Researchers from China have detailed a novel concept in cancer treatment, integrating two distinct immunotherapeutic modalities to overcome the limitations of current therapies. The approach, known as Dual Distinct Immunotherapy (DDI), strategically combines different treatments to achieve a synergistic effect. This review highlights the potential of DDI in enhancing therapeutic
Cancer
Researchers from Humanitas University in Milan, Italy have conducted a prospective observational study to evaluate the safety of romosozumab in women with cancer and osteoporosis, who are at high risk of fractures. The study involved 131 patients, with 19% having a history of cancer. The results showed that romosozumab was
Cancer
Researchers at Guangzhou Medical University have uncovered a crucial regulator of hierarchical cellular transitions in hepatocellular carcinoma (HCC), highlighting a potential target for cancer therapy. By analyzing public datasets and in vitro and in vivo models, the team identified the FOXM1/CEBPB axis as a key driver of developmental heterogeneity
